10-Q: GT Biopharma Reports First Quarter 2024 Results, Advances TriKE Platform Development

GT Biopharma reported a net loss of $2.27 million for the first quarter of 2024, while progressing its TriKE platform and preparing for clinical trials.

Summary

• GT Biopharma, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2024, reporting a net loss of $2.27 million, or $1.64 per share.
• The company's research and development expenses were $777,000, a decrease from $1.65 million in the same period last year, primarily due to reduced raw material purchases and consulting fees.
• Selling, general, and administrative expenses increased to $2.31 million from $2.02 million year-over-year, driven by higher legal and professional fees.
• GT Biopharma's cash and cash equivalents totaled $1.95 million, with short-term investments of $7.86 million as of March 31, 2024.
• The company anticipates its cash and investments are sufficient to fund operations for at least one year from the date of the report.
• A reverse stock split of 1-for-30 was implemented on February 2, 2024, reducing the number of outstanding shares to 1,380,633.
• The company is focused on advancing its TriKE platform, with GTB-3650 expected to enter clinical trials in the second half of 2024 and GTB-5550 anticipated to begin trials in the first half of 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress in its research and development programs, the financial results are concerning, with a significant increase in net loss. The need for potential future capital raises also adds uncertainty. The sentiment is therefore cautiously negative.

Positives

• The company has sufficient cash and short-term investments to fund operations for at least one year.
• Research and development expenses decreased due to the near completion of product development for GTB 3650.
• The company is progressing its next-generation TriKE candidates, GTB-3650 and GTB-5550, towards clinical trials.
• The design of the GTB-3650 clinical trial has been agreed upon with the FDA.

Negatives

• The company reported a net loss of $2.27 million for the quarter.
• Selling, general, and administrative expenses increased compared to the same period last year.
• The company has no approved products and has not generated any revenue from product sales.
• The company has sustained operating losses since inception and expects such losses to continue into the foreseeable future.

Risks

• The company's business is dependent on general economic conditions, which could be impacted by inflation, supply chain issues, and political volatility.
• The company may need to secure additional financing on acceptable terms, and there is no assurance that it will be able to do so.
• If the company does not generate sufficient cash flows, it may be forced to delay, reduce, or eliminate some or all of its discretionary spending.
• The company is involved in ongoing legal proceedings, including a lawsuit from a former executive and disputes over convertible promissory notes.

Future Outlook

The company anticipates advancing GTB-3650 into clinical trials in the second half of 2024 and GTB-5550 into clinical trials in the first half of 2025. The company also expects to continue its dialogue with the FDA regarding its IND application for GTB-3650.

Management Comments

• Management believes that the company has sufficient cash and cash equivalents, and short-term investments to fund its operations for more than twelve months from the date of this filing.
• Management is currently evaluating different strategies to obtain the required funding for future operations.

Industry Context

The company is operating in the competitive immuno-oncology space, focusing on novel therapies using its TriKE platform. The development of GTB-3650 and GTB-5550 aligns with the industry trend of leveraging natural killer cells for cancer treatment. The company's focus on both hematological malignancies and solid tumors positions it to address a broad range of unmet medical needs.

Comparison to Industry Standards

• GT Biopharma's approach of using TriKE technology to enhance natural killer cell activity is similar to other companies in the immuno-oncology space, such as Fate Therapeutics and Nkarta, which are also developing NK cell-based therapies.
• The company's focus on both hematological malignancies and solid tumors is comparable to companies like Adaptimmune and Iovance Biotherapeutics, which are developing cell therapies for a range of cancers.
• The company's reported net loss of $2.27 million for the quarter is typical for a clinical-stage biopharmaceutical company that is still in the research and development phase and has not yet generated revenue from product sales. This is similar to other companies in the sector at a similar stage of development.
• The company's cash position of $1.95 million and short-term investments of $7.86 million is relatively low compared to some of its peers, which may require the company to raise additional capital in the near future. Companies like Fate Therapeutics and Nkarta have significantly larger cash reserves due to previous capital raises.
• The company's timeline for clinical trials, with GTB-3650 expected to begin in the second half of 2024 and GTB-5550 in the first half of 2025, is consistent with the development timelines of other companies in the sector. However, delays in clinical trials are common in the industry, and the company's timeline may be subject to change.

Legal Proceedings

• The company is involved in a lawsuit filed by former interim CEO, Dr. Greg Berk, alleging discrimination and retaliation.
• The company is involved in an arbitration with its former CFO, Michael Handelman, where an interim award was issued in favor of the company.
• The company is involved in a legal dispute with TWF Global, LLC and Z One LLC regarding convertible promissory notes.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the need for potential future capital raises.
• Employees may be impacted by potential cost-cutting measures if the company does not secure sufficient funding.
• Customers and suppliers may be affected by any delays or changes in the company's operations due to financial constraints.
• Creditors may be concerned about the company's ability to repay its debts if it does not generate sufficient cash flow.

Next Steps

• The company plans to advance GTB-3650 into clinical trials in the second half of 2024.
• The company plans to advance GTB-5550 into clinical trials in the first half of 2025.
• The company will continue its dialogue with the FDA regarding its IND application for GTB-3650.
• The company will continue to negotiate the terms of a new scientific research agreement with the University of Minnesota.

Key Dates

Keywords

TriKE, Immuno-oncology, Biopharmaceutical, GTB-3650, GTB-5550, Clinical Trials, Natural Killer Cells, AML, MDS, B7-H3, CD33, Reverse Stock Split